{‘She possesses no qualifications’: this American scientific establishment braces for Høeg's appointment at the Food and Drug Administration.

Given that America continues making historic revisions to its immunization guidelines, one figure has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the global health crisis and has concentrated on potential deaths following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Health officials had intended to reveal sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with a large portion of the international standard with insufficient data for public health gain. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to head the office this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric shot schedules in the US to become more like the Danish model, a country with universal health coverage and a population about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

The appointee has no apparent experience in drug development, regulation or management, which has been standard for past leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in drug approvals.”

Previous commissioners of CBER would “understand regulatory frameworks and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

The drug center has an immense portfolio at the FDA, the former commissioner stated.

“The public just pays attention on the new drug program, but the off-patent medication office approves numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and more, and all of those have to be looked after,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a major leadership aspect to the job, which supervises more than 5,000 personnel. “It is a huge management job, if you perform it correctly,” Woodcock concluded.

Response and Disputed Policies

When asked about questions about Høeg’s credentials and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “concerns are based on flawed assumptions”.

“Her experience matches the functions of her job,” the spokesperson stated, noting the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that allegedly worried her preceding directors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards laxer oversight of all drugs, except for shots.”

Public History on Vaccines

With vaccines, Dr. Høeg has a clearer, if problematic, track record, Howard observe. She authored a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership featured revising rules for novel immunizations and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Høeg has according to sources proposed barring adolescent males from obtaining Covid vaccinations.

“She is an complete true believer who begins with her conclusions and tailors the evidence to fit the data in a extremely misleading, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|